CD274 and neoplasm: This strategy provided a 27-month PFS in our second-line patient, remodeling the tumor immune microenvironment from an immune-excluded/desert to an immune-inflamed phenotype, thereby overcoming baseline PD-L1 negativity and microsatellite stability.